nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—head and neck cancer	0.588	0.741	CbGaD
Sulindac—CYP1A1—head and neck cancer	0.126	0.159	CbGaD
Sulindac—PTGS2—head and neck cancer	0.0791	0.0996	CbGaD
Sulindac—Urine output—Hydroxyurea—head and neck cancer	0.00484	0.081	CcSEcCtD
Sulindac—MAPK3—exocrine gland—head and neck cancer	0.00243	0.069	CbGeAlD
Sulindac—MAPK3—mouth—head and neck cancer	0.00182	0.0516	CbGeAlD
Sulindac—AKR1B1—parotid gland—head and neck cancer	0.00175	0.0496	CbGeAlD
Sulindac—AKR1B1—saliva-secreting gland—head and neck cancer	0.00167	0.0475	CbGeAlD
Sulindac—Gastrointestinal perforation—Docetaxel—head and neck cancer	0.00167	0.028	CcSEcCtD
Sulindac—MAPK3—neck—head and neck cancer	0.00156	0.0441	CbGeAlD
Sulindac—AKR1B1—connective tissue—head and neck cancer	0.00154	0.0436	CbGeAlD
Sulindac—AKR1B1—epithelium—head and neck cancer	0.00146	0.0414	CbGeAlD
Sulindac—Peptic ulcer—Vinblastine—head and neck cancer	0.00138	0.0231	CcSEcCtD
Sulindac—AKR1B1—trachea—head and neck cancer	0.00129	0.0366	CbGeAlD
Sulindac—MAPK3—parotid gland—head and neck cancer	0.00127	0.0359	CbGeAlD
Sulindac—Bone marrow depression—Hydroxyurea—head and neck cancer	0.00124	0.0208	CcSEcCtD
Sulindac—Neuritis—Vinblastine—head and neck cancer	0.00123	0.0206	CcSEcCtD
Sulindac—Disseminated intravascular coagulation—Docetaxel—head and neck cancer	0.00122	0.0204	CcSEcCtD
Sulindac—MAPK3—saliva-secreting gland—head and neck cancer	0.00121	0.0344	CbGeAlD
Sulindac—PTGS2—cartilage tissue—head and neck cancer	0.00116	0.033	CbGeAlD
Sulindac—AKR1B1—lymphoid tissue—head and neck cancer	0.00112	0.0319	CbGeAlD
Sulindac—MAPK3—connective tissue—head and neck cancer	0.00111	0.0316	CbGeAlD
Sulindac—MAPK3—epithelium—head and neck cancer	0.00106	0.03	CbGeAlD
Sulindac—AKR1B1—thyroid gland—head and neck cancer	0.00102	0.029	CbGeAlD
Sulindac—Tenderness—Hydroxyurea—head and neck cancer	0.000962	0.0161	CcSEcCtD
Sulindac—MAPK3—trachea—head and neck cancer	0.000936	0.0265	CbGeAlD
Sulindac—AKR1B1—head—head and neck cancer	0.000906	0.0257	CbGeAlD
Sulindac—PPARD—lymphoid tissue—head and neck cancer	0.000884	0.0251	CbGeAlD
Sulindac—MAPK3—lymphoid tissue—head and neck cancer	0.000815	0.0231	CbGeAlD
Sulindac—PPARD—thyroid gland—head and neck cancer	0.000803	0.0228	CbGeAlD
Sulindac—MAPK3—thyroid gland—head and neck cancer	0.00074	0.021	CbGeAlD
Sulindac—PPARD—head—head and neck cancer	0.000713	0.0202	CbGeAlD
Sulindac—Tenderness—Fluorouracil—head and neck cancer	0.000692	0.0116	CcSEcCtD
Sulindac—Hepatic failure—Hydroxyurea—head and neck cancer	0.000678	0.0114	CcSEcCtD
Sulindac—MAPK3—head—head and neck cancer	0.000657	0.0186	CbGeAlD
Sulindac—Leukocytosis—Fluorouracil—head and neck cancer	0.000643	0.0108	CcSEcCtD
Sulindac—AKR1B1—lymph node—head and neck cancer	0.000634	0.018	CbGeAlD
Sulindac—Neuritis—Docetaxel—head and neck cancer	0.000584	0.00978	CcSEcCtD
Sulindac—Pleural effusion—Docetaxel—head and neck cancer	0.000569	0.00953	CcSEcCtD
Sulindac—CYP1A1—mouth—head and neck cancer	0.000563	0.016	CbGeAlD
Sulindac—Coma—Fluorouracil—head and neck cancer	0.000552	0.00924	CcSEcCtD
Sulindac—Pancytopenia—Vinblastine—head and neck cancer	0.000548	0.00918	CcSEcCtD
Sulindac—Ageusia—Docetaxel—head and neck cancer	0.000538	0.00901	CcSEcCtD
Sulindac—Pancreatitis—Hydroxyurea—head and neck cancer	0.000516	0.00865	CcSEcCtD
Sulindac—Depression—Vinblastine—head and neck cancer	0.000513	0.0086	CcSEcCtD
Sulindac—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000505	0.00845	CcSEcCtD
Sulindac—Pancytopenia—Hydroxyurea—head and neck cancer	0.0005	0.00837	CcSEcCtD
Sulindac—Photosensitivity—Fluorouracil—head and neck cancer	0.000499	0.00836	CcSEcCtD
Sulindac—PPARD—lymph node—head and neck cancer	0.000499	0.0142	CbGeAlD
Sulindac—Dysuria—Hydroxyurea—head and neck cancer	0.000492	0.00825	CcSEcCtD
Sulindac—Neutropenia—Hydroxyurea—head and neck cancer	0.000492	0.00825	CcSEcCtD
Sulindac—Agranulocytosis—Vinblastine—head and neck cancer	0.00048	0.00805	CcSEcCtD
Sulindac—PTGS2—mouth—head and neck cancer	0.000473	0.0134	CbGeAlD
Sulindac—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00046	0.00771	CcSEcCtD
Sulindac—MAPK3—lymph node—head and neck cancer	0.00046	0.013	CbGeAlD
Sulindac—Hearing impaired—Docetaxel—head and neck cancer	0.000458	0.00767	CcSEcCtD
Sulindac—Stomatitis—Hydroxyurea—head and neck cancer	0.000458	0.00766	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000438	0.00734	CcSEcCtD
Sulindac—Colitis—Docetaxel—head and neck cancer	0.000419	0.00701	CcSEcCtD
Sulindac—Alopecia—Vinblastine—head and neck cancer	0.000408	0.00684	CcSEcCtD
Sulindac—CYP1A1—parotid gland—head and neck cancer	0.000392	0.0111	CbGeAlD
Sulindac—Muscular weakness—Fluorouracil—head and neck cancer	0.000387	0.00648	CcSEcCtD
Sulindac—Chills—Hydroxyurea—head and neck cancer	0.000378	0.00633	CcSEcCtD
Sulindac—Eosinophilia—Fluorouracil—head and neck cancer	0.000375	0.00628	CcSEcCtD
Sulindac—Ill-defined disorder—Vinblastine—head and neck cancer	0.000373	0.00625	CcSEcCtD
Sulindac—Alopecia—Hydroxyurea—head and neck cancer	0.000372	0.00624	CcSEcCtD
Sulindac—Anaemia—Vinblastine—head and neck cancer	0.000372	0.00623	CcSEcCtD
Sulindac—Malaise—Vinblastine—head and neck cancer	0.000363	0.00608	CcSEcCtD
Sulindac—Vertigo—Vinblastine—head and neck cancer	0.000361	0.00605	CcSEcCtD
Sulindac—Leukopenia—Vinblastine—head and neck cancer	0.00036	0.00603	CcSEcCtD
Sulindac—Pancytopenia—Fluorouracil—head and neck cancer	0.00036	0.00603	CcSEcCtD
Sulindac—Hepatic failure—Docetaxel—head and neck cancer	0.000352	0.0059	CcSEcCtD
Sulindac—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000349	0.00584	CcSEcCtD
Sulindac—Convulsion—Vinblastine—head and neck cancer	0.000349	0.00584	CcSEcCtD
Sulindac—Hypertension—Vinblastine—head and neck cancer	0.000347	0.00582	CcSEcCtD
Sulindac—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000346	0.00579	CcSEcCtD
Sulindac—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00034	0.0057	CcSEcCtD
Sulindac—Pneumonia—Fluorouracil—head and neck cancer	0.00034	0.00569	CcSEcCtD
Sulindac—Anaemia—Hydroxyurea—head and neck cancer	0.000339	0.00568	CcSEcCtD
Sulindac—Discomfort—Vinblastine—head and neck cancer	0.000338	0.00567	CcSEcCtD
Sulindac—Visual disturbance—Docetaxel—head and neck cancer	0.000334	0.00559	CcSEcCtD
Sulindac—Renal impairment—Docetaxel—head and neck cancer	0.000333	0.00557	CcSEcCtD
Sulindac—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000331	0.00555	CcSEcCtD
Sulindac—Malaise—Hydroxyurea—head and neck cancer	0.000331	0.00554	CcSEcCtD
Sulindac—Stomatitis—Fluorouracil—head and neck cancer	0.000329	0.00552	CcSEcCtD
Sulindac—Conjunctivitis—Fluorouracil—head and neck cancer	0.000328	0.0055	CcSEcCtD
Sulindac—Leukopenia—Hydroxyurea—head and neck cancer	0.000328	0.0055	CcSEcCtD
Sulindac—CYP1A1—epithelium—head and neck cancer	0.000327	0.00929	CbGeAlD
Sulindac—Thrombocytopenia—Vinblastine—head and neck cancer	0.000321	0.00538	CcSEcCtD
Sulindac—Epistaxis—Fluorouracil—head and neck cancer	0.000319	0.00534	CcSEcCtD
Sulindac—Convulsion—Hydroxyurea—head and neck cancer	0.000318	0.00532	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000316	0.0053	CcSEcCtD
Sulindac—Agranulocytosis—Fluorouracil—head and neck cancer	0.000315	0.00528	CcSEcCtD
Sulindac—Anorexia—Vinblastine—head and neck cancer	0.000313	0.00524	CcSEcCtD
Sulindac—Discomfort—Hydroxyurea—head and neck cancer	0.000309	0.00517	CcSEcCtD
Sulindac—PTGS1—connective tissue—head and neck cancer	0.000303	0.00859	CbGeAlD
Sulindac—Oedema—Hydroxyurea—head and neck cancer	0.000299	0.00501	CcSEcCtD
Sulindac—Paraesthesia—Vinblastine—head and neck cancer	0.000295	0.00494	CcSEcCtD
Sulindac—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000293	0.00491	CcSEcCtD
Sulindac—PTGS2—connective tissue—head and neck cancer	0.00029	0.00821	CbGeAlD
Sulindac—CYP1A1—trachea—head and neck cancer	0.00029	0.00821	CbGeAlD
Sulindac—PTGS1—epithelium—head and neck cancer	0.000288	0.00816	CbGeAlD
Sulindac—Anorexia—Hydroxyurea—head and neck cancer	0.000285	0.00478	CcSEcCtD
Sulindac—Decreased appetite—Vinblastine—head and neck cancer	0.000285	0.00478	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000285	0.00477	CcSEcCtD
Sulindac—Constipation—Vinblastine—head and neck cancer	0.000281	0.0047	CcSEcCtD
Sulindac—PTGS2—epithelium—head and neck cancer	0.000275	0.0078	CbGeAlD
Sulindac—Arrhythmia—Fluorouracil—head and neck cancer	0.000271	0.00454	CcSEcCtD
Sulindac—Feeling abnormal—Vinblastine—head and neck cancer	0.000271	0.00453	CcSEcCtD
Sulindac—Bronchospasm—Docetaxel—head and neck cancer	0.000269	0.00451	CcSEcCtD
Sulindac—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000268	0.0045	CcSEcCtD
Sulindac—Alopecia—Fluorouracil—head and neck cancer	0.000268	0.00449	CcSEcCtD
Sulindac—Dyspnoea—Hydroxyurea—head and neck cancer	0.000267	0.00447	CcSEcCtD
Sulindac—Somnolence—Hydroxyurea—head and neck cancer	0.000266	0.00446	CcSEcCtD
Sulindac—Dyspepsia—Hydroxyurea—head and neck cancer	0.000264	0.00441	CcSEcCtD
Sulindac—Decreased appetite—Hydroxyurea—head and neck cancer	0.00026	0.00436	CcSEcCtD
Sulindac—Pancytopenia—Docetaxel—head and neck cancer	0.00026	0.00435	CcSEcCtD
Sulindac—Fatigue—Hydroxyurea—head and neck cancer	0.000258	0.00432	CcSEcCtD
Sulindac—Constipation—Hydroxyurea—head and neck cancer	0.000256	0.00429	CcSEcCtD
Sulindac—Neutropenia—Docetaxel—head and neck cancer	0.000256	0.00428	CcSEcCtD
Sulindac—PTGS1—trachea—head and neck cancer	0.000254	0.00721	CbGeAlD
Sulindac—Vision blurred—Fluorouracil—head and neck cancer	0.000249	0.00417	CcSEcCtD
Sulindac—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000247	0.00413	CcSEcCtD
Sulindac—Pneumonia—Docetaxel—head and neck cancer	0.000245	0.00411	CcSEcCtD
Sulindac—Anaemia—Fluorouracil—head and neck cancer	0.000244	0.00409	CcSEcCtD
Sulindac—PTGS2—trachea—head and neck cancer	0.000243	0.00689	CbGeAlD
Sulindac—Hypersensitivity—Vinblastine—head and neck cancer	0.000242	0.00405	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000242	0.00405	CcSEcCtD
Sulindac—Renal failure—Docetaxel—head and neck cancer	0.00024	0.00402	CcSEcCtD
Sulindac—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000239	0.004	CcSEcCtD
Sulindac—Stomatitis—Docetaxel—head and neck cancer	0.000238	0.00398	CcSEcCtD
Sulindac—Jaundice—Docetaxel—head and neck cancer	0.000238	0.00398	CcSEcCtD
Sulindac—Conjunctivitis—Docetaxel—head and neck cancer	0.000237	0.00397	CcSEcCtD
Sulindac—Body temperature increased—Hydroxyurea—head and neck cancer	0.000237	0.00396	CcSEcCtD
Sulindac—Leukopenia—Fluorouracil—head and neck cancer	0.000236	0.00396	CcSEcCtD
Sulindac—Asthenia—Vinblastine—head and neck cancer	0.000236	0.00394	CcSEcCtD
Sulindac—CYP1A2—thyroid gland—head and neck cancer	0.000232	0.00658	CbGeAlD
Sulindac—Epistaxis—Docetaxel—head and neck cancer	0.00023	0.00385	CcSEcCtD
Sulindac—CYP1A1—thyroid gland—head and neck cancer	0.000229	0.0065	CbGeAlD
Sulindac—Convulsion—Fluorouracil—head and neck cancer	0.000229	0.00383	CcSEcCtD
Sulindac—Agranulocytosis—Docetaxel—head and neck cancer	0.000228	0.00381	CcSEcCtD
Sulindac—Myalgia—Fluorouracil—head and neck cancer	0.000225	0.00377	CcSEcCtD
Sulindac—Chest pain—Fluorouracil—head and neck cancer	0.000225	0.00377	CcSEcCtD
Sulindac—Diarrhoea—Vinblastine—head and neck cancer	0.000225	0.00376	CcSEcCtD
Sulindac—Discomfort—Fluorouracil—head and neck cancer	0.000222	0.00372	CcSEcCtD
Sulindac—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000221	0.00369	CcSEcCtD
Sulindac—ALB—lymph node—head and neck cancer	0.000219	0.00622	CbGeAlD
Sulindac—Hepatitis—Docetaxel—head and neck cancer	0.000219	0.00367	CcSEcCtD
Sulindac—Dizziness—Vinblastine—head and neck cancer	0.000217	0.00364	CcSEcCtD
Sulindac—Oedema—Fluorouracil—head and neck cancer	0.000215	0.00361	CcSEcCtD
Sulindac—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000215	0.00361	CcSEcCtD
Sulindac—Asthenia—Hydroxyurea—head and neck cancer	0.000215	0.0036	CcSEcCtD
Sulindac—PTGS2—lymphoid tissue—head and neck cancer	0.000212	0.00601	CbGeAlD
Sulindac—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000211	0.00353	CcSEcCtD
Sulindac—Visual impairment—Docetaxel—head and neck cancer	0.000211	0.00353	CcSEcCtD
Sulindac—Tachycardia—Fluorouracil—head and neck cancer	0.00021	0.00352	CcSEcCtD
Sulindac—Vomiting—Vinblastine—head and neck cancer	0.000209	0.0035	CcSEcCtD
Sulindac—Erythema multiforme—Docetaxel—head and neck cancer	0.000207	0.00347	CcSEcCtD
Sulindac—Headache—Vinblastine—head and neck cancer	0.000206	0.00344	CcSEcCtD
Sulindac—Anorexia—Fluorouracil—head and neck cancer	0.000205	0.00344	CcSEcCtD
Sulindac—Diarrhoea—Hydroxyurea—head and neck cancer	0.000205	0.00343	CcSEcCtD
Sulindac—CYP1A1—head—head and neck cancer	0.000203	0.00576	CbGeAlD
Sulindac—Flushing—Docetaxel—head and neck cancer	0.000203	0.0034	CcSEcCtD
Sulindac—Hypotension—Fluorouracil—head and neck cancer	0.000201	0.00337	CcSEcCtD
Sulindac—PTGS1—thyroid gland—head and neck cancer	0.000201	0.00571	CbGeAlD
Sulindac—Dizziness—Hydroxyurea—head and neck cancer	0.000198	0.00332	CcSEcCtD
Sulindac—Chills—Docetaxel—head and neck cancer	0.000196	0.00329	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000196	0.00329	CcSEcCtD
Sulindac—Arrhythmia—Docetaxel—head and neck cancer	0.000196	0.00328	CcSEcCtD
Sulindac—Nausea—Vinblastine—head and neck cancer	0.000195	0.00327	CcSEcCtD
Sulindac—Insomnia—Fluorouracil—head and neck cancer	0.000195	0.00326	CcSEcCtD
Sulindac—Paraesthesia—Fluorouracil—head and neck cancer	0.000193	0.00324	CcSEcCtD
Sulindac—Alopecia—Docetaxel—head and neck cancer	0.000193	0.00324	CcSEcCtD
Sulindac—Dyspnoea—Fluorouracil—head and neck cancer	0.000192	0.00322	CcSEcCtD
Sulindac—Somnolence—Fluorouracil—head and neck cancer	0.000192	0.00321	CcSEcCtD
Sulindac—Vomiting—Hydroxyurea—head and neck cancer	0.00019	0.00319	CcSEcCtD
Sulindac—Dyspepsia—Fluorouracil—head and neck cancer	0.00019	0.00318	CcSEcCtD
Sulindac—Rash—Hydroxyurea—head and neck cancer	0.000189	0.00316	CcSEcCtD
Sulindac—Dermatitis—Hydroxyurea—head and neck cancer	0.000189	0.00316	CcSEcCtD
Sulindac—Headache—Hydroxyurea—head and neck cancer	0.000188	0.00314	CcSEcCtD
Sulindac—Decreased appetite—Fluorouracil—head and neck cancer	0.000187	0.00314	CcSEcCtD
Sulindac—Dysgeusia—Docetaxel—head and neck cancer	0.000187	0.00313	CcSEcCtD
Sulindac—PTGS1—head—head and neck cancer	0.000178	0.00506	CbGeAlD
Sulindac—Nausea—Hydroxyurea—head and neck cancer	0.000178	0.00298	CcSEcCtD
Sulindac—Feeling abnormal—Fluorouracil—head and neck cancer	0.000178	0.00297	CcSEcCtD
Sulindac—Anaemia—Docetaxel—head and neck cancer	0.000176	0.00295	CcSEcCtD
Sulindac—Urticaria—Fluorouracil—head and neck cancer	0.000171	0.00287	CcSEcCtD
Sulindac—Syncope—Docetaxel—head and neck cancer	0.000171	0.00286	CcSEcCtD
Sulindac—PTGS2—head—head and neck cancer	0.000171	0.00484	CbGeAlD
Sulindac—Leukopenia—Docetaxel—head and neck cancer	0.000171	0.00286	CcSEcCtD
Sulindac—Body temperature increased—Fluorouracil—head and neck cancer	0.00017	0.00285	CcSEcCtD
Sulindac—Palpitations—Docetaxel—head and neck cancer	0.000168	0.00282	CcSEcCtD
Sulindac—Loss of consciousness—Docetaxel—head and neck cancer	0.000167	0.00281	CcSEcCtD
Sulindac—Convulsion—Docetaxel—head and neck cancer	0.000165	0.00277	CcSEcCtD
Sulindac—Hypertension—Docetaxel—head and neck cancer	0.000165	0.00276	CcSEcCtD
Sulindac—Arthralgia—Docetaxel—head and neck cancer	0.000162	0.00272	CcSEcCtD
Sulindac—Chest pain—Docetaxel—head and neck cancer	0.000162	0.00272	CcSEcCtD
Sulindac—Myalgia—Docetaxel—head and neck cancer	0.000162	0.00272	CcSEcCtD
Sulindac—Hypersensitivity—Fluorouracil—head and neck cancer	0.000159	0.00266	CcSEcCtD
Sulindac—Oedema—Docetaxel—head and neck cancer	0.000156	0.00261	CcSEcCtD
Sulindac—Anaphylactic shock—Docetaxel—head and neck cancer	0.000156	0.00261	CcSEcCtD
Sulindac—Shock—Docetaxel—head and neck cancer	0.000153	0.00256	CcSEcCtD
Sulindac—Pruritus—Fluorouracil—head and neck cancer	0.000152	0.00255	CcSEcCtD
Sulindac—Thrombocytopenia—Docetaxel—head and neck cancer	0.000152	0.00255	CcSEcCtD
Sulindac—Tachycardia—Docetaxel—head and neck cancer	0.000152	0.00254	CcSEcCtD
Sulindac—Anorexia—Docetaxel—head and neck cancer	0.000148	0.00248	CcSEcCtD
Sulindac—Diarrhoea—Fluorouracil—head and neck cancer	0.000147	0.00247	CcSEcCtD
Sulindac—Hypotension—Docetaxel—head and neck cancer	0.000145	0.00243	CcSEcCtD
Sulindac—Dizziness—Fluorouracil—head and neck cancer	0.000142	0.00239	CcSEcCtD
Sulindac—CYP1A1—lymph node—head and neck cancer	0.000142	0.00403	CbGeAlD
Sulindac—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000142	0.00237	CcSEcCtD
Sulindac—Insomnia—Docetaxel—head and neck cancer	0.000141	0.00236	CcSEcCtD
Sulindac—Paraesthesia—Docetaxel—head and neck cancer	0.00014	0.00234	CcSEcCtD
Sulindac—Dyspnoea—Docetaxel—head and neck cancer	0.000139	0.00232	CcSEcCtD
Sulindac—Somnolence—Docetaxel—head and neck cancer	0.000138	0.00232	CcSEcCtD
Sulindac—Vomiting—Fluorouracil—head and neck cancer	0.000137	0.00229	CcSEcCtD
Sulindac—Dyspepsia—Docetaxel—head and neck cancer	0.000137	0.00229	CcSEcCtD
Sulindac—Rash—Fluorouracil—head and neck cancer	0.000136	0.00228	CcSEcCtD
Sulindac—Dermatitis—Fluorouracil—head and neck cancer	0.000136	0.00227	CcSEcCtD
Sulindac—Decreased appetite—Docetaxel—head and neck cancer	0.000135	0.00226	CcSEcCtD
Sulindac—Headache—Fluorouracil—head and neck cancer	0.000135	0.00226	CcSEcCtD
Sulindac—Fatigue—Docetaxel—head and neck cancer	0.000134	0.00225	CcSEcCtD
Sulindac—Constipation—Docetaxel—head and neck cancer	0.000133	0.00223	CcSEcCtD
Sulindac—Feeling abnormal—Docetaxel—head and neck cancer	0.000128	0.00215	CcSEcCtD
Sulindac—Nausea—Fluorouracil—head and neck cancer	0.000128	0.00214	CcSEcCtD
Sulindac—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000127	0.00213	CcSEcCtD
Sulindac—PTGS1—lymph node—head and neck cancer	0.000125	0.00354	CbGeAlD
Sulindac—Body temperature increased—Docetaxel—head and neck cancer	0.000123	0.00206	CcSEcCtD
Sulindac—PTGS2—lymph node—head and neck cancer	0.000119	0.00339	CbGeAlD
Sulindac—Hypersensitivity—Docetaxel—head and neck cancer	0.000115	0.00192	CcSEcCtD
Sulindac—Asthenia—Docetaxel—head and neck cancer	0.000112	0.00187	CcSEcCtD
Sulindac—Pruritus—Docetaxel—head and neck cancer	0.00011	0.00184	CcSEcCtD
Sulindac—Diarrhoea—Docetaxel—head and neck cancer	0.000106	0.00178	CcSEcCtD
Sulindac—Dizziness—Docetaxel—head and neck cancer	0.000103	0.00172	CcSEcCtD
Sulindac—Vomiting—Docetaxel—head and neck cancer	9.89e-05	0.00166	CcSEcCtD
Sulindac—Rash—Docetaxel—head and neck cancer	9.81e-05	0.00164	CcSEcCtD
Sulindac—Dermatitis—Docetaxel—head and neck cancer	9.8e-05	0.00164	CcSEcCtD
Sulindac—Headache—Docetaxel—head and neck cancer	9.74e-05	0.00163	CcSEcCtD
Sulindac—Nausea—Docetaxel—head and neck cancer	9.24e-05	0.00155	CcSEcCtD
Sulindac—MAPK3—Cellular responses to stress—STAT3—head and neck cancer	3.25e-05	0.000293	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.24e-05	0.000292	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—head and neck cancer	3.24e-05	0.000291	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	3.23e-05	0.000291	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.21e-05	0.000289	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—head and neck cancer	3.21e-05	0.000289	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—head and neck cancer	3.19e-05	0.000288	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	3.13e-05	0.000282	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—AKT1—head and neck cancer	3.13e-05	0.000281	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—AKT1—head and neck cancer	3.11e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—STAT3—head and neck cancer	3.1e-05	0.000279	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—AKT1—head and neck cancer	3.1e-05	0.000279	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—AKT1—head and neck cancer	3.08e-05	0.000277	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—AKT1—head and neck cancer	3.07e-05	0.000276	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—STAT3—head and neck cancer	3.05e-05	0.000274	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—PIK3CA—head and neck cancer	3.05e-05	0.000274	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	3.02e-05	0.000272	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—AKT1—head and neck cancer	3.01e-05	0.000271	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	2.96e-05	0.000266	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—MAPK1—head and neck cancer	2.95e-05	0.000266	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—UROD—head and neck cancer	2.92e-05	0.000263	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GRP—head and neck cancer	2.92e-05	0.000263	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	2.9e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	2.89e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—AKT1—head and neck cancer	2.88e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—AKT1—head and neck cancer	2.88e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	2.88e-05	0.00026	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.87e-05	0.000258	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—AKT1—head and neck cancer	2.86e-05	0.000257	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.84e-05	0.000256	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT6—head and neck cancer	2.83e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—AKT1—head and neck cancer	2.83e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—AKT1—head and neck cancer	2.82e-05	0.000254	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—head and neck cancer	2.82e-05	0.000254	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	2.82e-05	0.000254	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	2.81e-05	0.000253	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	2.8e-05	0.000252	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	2.8e-05	0.000252	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—head and neck cancer	2.79e-05	0.000251	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—MAPK1—head and neck cancer	2.77e-05	0.00025	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—EGFR—head and neck cancer	2.77e-05	0.000249	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—AKT1—head and neck cancer	2.74e-05	0.000247	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CASP8—head and neck cancer	2.73e-05	0.000246	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—AKT1—head and neck cancer	2.73e-05	0.000246	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.72e-05	0.000245	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2.71e-05	0.000244	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2—head and neck cancer	2.71e-05	0.000244	CbGpPWpGaD
Sulindac—MAPK3—M Phase—MAPK1—head and neck cancer	2.7e-05	0.000243	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NAT2—head and neck cancer	2.7e-05	0.000243	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCND1—head and neck cancer	2.64e-05	0.000238	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	2.55e-05	0.00023	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PTEN—head and neck cancer	2.55e-05	0.00023	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	2.53e-05	0.000228	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—YAP1—head and neck cancer	2.51e-05	0.000226	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MAPK1—head and neck cancer	2.51e-05	0.000226	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—EGFR—head and neck cancer	2.51e-05	0.000226	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—AKT1—head and neck cancer	2.49e-05	0.000224	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—head and neck cancer	2.48e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—MAPK1—head and neck cancer	2.48e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	2.45e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	2.41e-05	0.000217	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—PIK3CA—head and neck cancer	2.4e-05	0.000217	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	2.39e-05	0.000215	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—DPYD—head and neck cancer	2.37e-05	0.000213	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CCND1—head and neck cancer	2.36e-05	0.000213	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—BCL2—head and neck cancer	2.35e-05	0.000211	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—head and neck cancer	2.3e-05	0.000207	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2—head and neck cancer	2.3e-05	0.000207	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—STAT3—head and neck cancer	2.28e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.28e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	2.28e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	2.28e-05	0.000205	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.27e-05	0.000204	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—head and neck cancer	2.26e-05	0.000204	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.25e-05	0.000203	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—YAP1—head and neck cancer	2.25e-05	0.000202	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—head and neck cancer	2.23e-05	0.0002	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MAPK3—head and neck cancer	2.18e-05	0.000196	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NAT2—head and neck cancer	2.14e-05	0.000193	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	2.14e-05	0.000193	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CCND1—head and neck cancer	2.11e-05	0.00019	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MAPK1—head and neck cancer	2.07e-05	0.000187	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EGFR—head and neck cancer	2.07e-05	0.000187	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.02e-05	0.000182	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—head and neck cancer	2.01e-05	0.000181	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—head and neck cancer	1.99e-05	0.000179	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	1.98e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—STAT3—head and neck cancer	1.97e-05	0.000177	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—head and neck cancer	1.97e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—head and neck cancer	1.96e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—head and neck cancer	1.95e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2L1—head and neck cancer	1.95e-05	0.000175	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PTEN—head and neck cancer	1.94e-05	0.000175	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	1.91e-05	0.000172	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NAT2—head and neck cancer	1.9e-05	0.000171	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MAPK3—head and neck cancer	1.88e-05	0.00017	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—DPYD—head and neck cancer	1.88e-05	0.000169	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MAPK1—head and neck cancer	1.85e-05	0.000167	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.84e-05	0.000166	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.82e-05	0.000164	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	1.82e-05	0.000164	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PIK3CA—head and neck cancer	1.8e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MAPK1—head and neck cancer	1.79e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EGFR—head and neck cancer	1.79e-05	0.000161	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—YAP1—head and neck cancer	1.78e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—MAPK1—head and neck cancer	1.76e-05	0.000158	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—head and neck cancer	1.74e-05	0.000157	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—NOTCH1—head and neck cancer	1.74e-05	0.000157	CbGpPWpGaD
Sulindac—ALB—Metabolism—NAT2—head and neck cancer	1.73e-05	0.000156	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	1.72e-05	0.000155	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTEN—head and neck cancer	1.72e-05	0.000154	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.69e-05	0.000152	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—DPYD—head and neck cancer	1.67e-05	0.00015	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—head and neck cancer	1.67e-05	0.00015	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MAPK1—head and neck cancer	1.66e-05	0.000149	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	1.64e-05	0.000148	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOTCH1—head and neck cancer	1.61e-05	0.000145	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	1.61e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CASP8—head and neck cancer	1.59e-05	0.000143	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—YAP1—head and neck cancer	1.58e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MAPK1—head and neck cancer	1.58e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—head and neck cancer	1.58e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDH1—head and neck cancer	1.57e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—head and neck cancer	1.52e-05	0.000137	CbGpPWpGaD
Sulindac—ALB—Metabolism—DPYD—head and neck cancer	1.52e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—head and neck cancer	1.47e-05	0.000133	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.47e-05	0.000133	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—head and neck cancer	1.47e-05	0.000132	CbGpPWpGaD
Sulindac—ALB—Metabolism—YAP1—head and neck cancer	1.44e-05	0.00013	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—head and neck cancer	1.44e-05	0.000129	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.42e-05	0.000128	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—head and neck cancer	1.41e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—head and neck cancer	1.39e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—head and neck cancer	1.37e-05	0.000123	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2—head and neck cancer	1.37e-05	0.000123	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TYMS—head and neck cancer	1.35e-05	0.000122	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTM1—head and neck cancer	1.33e-05	0.00012	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—head and neck cancer	1.32e-05	0.000119	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.29e-05	0.000116	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GPX1—head and neck cancer	1.28e-05	0.000115	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.28e-05	0.000115	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—head and neck cancer	1.27e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—head and neck cancer	1.27e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—head and neck cancer	1.27e-05	0.000114	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP1A1—head and neck cancer	1.26e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—head and neck cancer	1.24e-05	0.000112	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NAT2—head and neck cancer	1.21e-05	0.000109	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—head and neck cancer	1.21e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—head and neck cancer	1.2e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—head and neck cancer	1.2e-05	0.000108	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.19e-05	0.000107	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.17e-05	0.000105	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.16e-05	0.000105	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—head and neck cancer	1.13e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOTCH1—head and neck cancer	1.13e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—head and neck cancer	1.12e-05	0.000101	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—head and neck cancer	1.1e-05	9.94e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.08e-05	9.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TYMS—head and neck cancer	1.07e-05	9.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DPYD—head and neck cancer	1.06e-05	9.58e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—head and neck cancer	1.06e-05	9.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—head and neck cancer	1.05e-05	9.41e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.04e-05	9.35e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.04e-05	9.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPX1—head and neck cancer	1.01e-05	9.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—head and neck cancer	1.01e-05	9.12e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—YAP1—head and neck cancer	1.01e-05	9.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—MAPK1—head and neck cancer	1.01e-05	9.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—head and neck cancer	1.01e-05	9.07e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—head and neck cancer	1e-05	9.04e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—head and neck cancer	9.88e-06	8.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOTCH1—head and neck cancer	9.6e-06	8.65e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TYMS—head and neck cancer	9.51e-06	8.56e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.46e-06	8.52e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—head and neck cancer	9.4e-06	8.46e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—head and neck cancer	9.39e-06	8.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—head and neck cancer	9.35e-06	8.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK1—head and neck cancer	9.21e-06	8.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—head and neck cancer	9.21e-06	8.29e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPX1—head and neck cancer	9e-06	8.1e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—head and neck cancer	8.88e-06	7.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—head and neck cancer	8.74e-06	7.87e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TYMS—head and neck cancer	8.67e-06	7.8e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—head and neck cancer	8.57e-06	7.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MAPK1—head and neck cancer	8.5e-06	7.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—head and neck cancer	8.5e-06	7.65e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK1—head and neck cancer	8.45e-06	7.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	8.25e-06	7.43e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPX1—head and neck cancer	8.21e-06	7.39e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—head and neck cancer	8.12e-06	7.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—head and neck cancer	8.09e-06	7.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—head and neck cancer	7.99e-06	7.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—head and neck cancer	7.78e-06	7.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.59e-06	6.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—head and neck cancer	7.59e-06	6.83e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—head and neck cancer	7.52e-06	6.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—head and neck cancer	7.39e-06	6.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—head and neck cancer	7.38e-06	6.64e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—head and neck cancer	7.33e-06	6.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—head and neck cancer	7.32e-06	6.59e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.32e-06	6.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—head and neck cancer	7.14e-06	6.43e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—head and neck cancer	7.09e-06	6.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—head and neck cancer	6.82e-06	6.14e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—head and neck cancer	6.78e-06	6.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.67e-06	6.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.62e-06	5.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—head and neck cancer	6.61e-06	5.95e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—head and neck cancer	6.56e-06	5.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—head and neck cancer	6.55e-06	5.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—head and neck cancer	6.53e-06	5.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—head and neck cancer	6.49e-06	5.84e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—head and neck cancer	6.22e-06	5.6e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TYMS—head and neck cancer	6.06e-06	5.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—head and neck cancer	6.03e-06	5.42e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—head and neck cancer	5.99e-06	5.4e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—head and neck cancer	5.99e-06	5.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK1—head and neck cancer	5.95e-06	5.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—head and neck cancer	5.95e-06	5.36e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPX1—head and neck cancer	5.74e-06	5.17e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—head and neck cancer	5.68e-06	5.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—head and neck cancer	5.56e-06	5.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—head and neck cancer	5.31e-06	4.78e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—head and neck cancer	5.3e-06	4.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—head and neck cancer	5.21e-06	4.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—head and neck cancer	5.17e-06	4.65e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK1—head and neck cancer	5.06e-06	4.55e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—head and neck cancer	5.05e-06	4.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—head and neck cancer	5e-06	4.5e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—head and neck cancer	4.83e-06	4.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—head and neck cancer	4.78e-06	4.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.67e-06	4.2e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—head and neck cancer	4.63e-06	4.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—head and neck cancer	4.62e-06	4.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—head and neck cancer	4.39e-06	3.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—head and neck cancer	4.22e-06	3.8e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—head and neck cancer	4.21e-06	3.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—head and neck cancer	4.06e-06	3.65e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—head and neck cancer	3.78e-06	3.4e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—head and neck cancer	3.67e-06	3.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—head and neck cancer	3.58e-06	3.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—head and neck cancer	3.38e-06	3.04e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—head and neck cancer	3.26e-06	2.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—head and neck cancer	3e-06	2.7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—head and neck cancer	2.97e-06	2.68e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—head and neck cancer	2.95e-06	2.65e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—head and neck cancer	2.66e-06	2.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—head and neck cancer	2.43e-06	2.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—head and neck cancer	2.08e-06	1.87e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—head and neck cancer	1.7e-06	1.53e-05	CbGpPWpGaD
